Full-Time
Contract Development and Manufacturing Manager
Updated on 8/23/2026
Amgen
10,001+ employees
Biotech company creating biologic medicines
No salary listed
Hyderabad, Telangana, India
Remote
Occasional domestic and international travel required.
Bachelor's
 Biology & Biotech (1) |
|---|
Get referred to Amgen
See people who can refer or advise you
- Any degree.
- 8-13 years of experience.
- Experience leading external manufacturing programs at contract development and manufacturing organizations, preferably in peptides or related modalities.
- Demonstrated experience in technology transfer, scale-up, and good manufacturing practice readiness.
- Strong understanding of drug substance development through commercial manufacturing.
- Experience working closely with manufacturing sites in a site-facing role.
- Ability to operate effectively in a matrixed, global organization with shared accountabilities.
- Strong project leadership, stakeholder management, and communication skills.
- Ability to proactively identify and resolve complex technical and operational risks.
- Serve as program lead for external peptide manufacturing, accountable for end-to-end execution across development, clinical, and commercial stages.
- Act as a primary interface with contract development and manufacturing organizations, working alongside the site lead to ensure alignment on program priorities and deliverables.
- Drive technology transfer, scale-up, and process readiness in collaboration with Process Development and site teams.
- Provide oversight of manufacturing activities to ensure readiness for good manufacturing practice operations.
- Identify and manage program risks, including technical, supply, and regulatory risks, and drive mitigation strategies.
- Partner cross-functionally with Process Development, Analytical, Quality, Supply Chain, and Regulatory to ensure integrated execution.
- Support sourcing and externalization activities, including Scope of Work development and supplier engagement.
- Ensure adherence to current good manufacturing practice requirements and business processes, including deviations, change control, and investigations.
- Monitor and manage program performance across timeline, quality, and cost, escalating issues as needed.
- Present program updates, risks, and recommendations to senior management.
- Travel domestically and internationally occasionally.
- Experience leading external manufacturing programs at contract development and manufacturing organizations in peptides or related modalities.
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
- Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
- Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.
What critics are saying
- FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
- Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
- Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.
What makes Amgen unique
- Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
- MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
- Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.
Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.
Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.
Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.
Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.